Amin launches new osteoporosis drug Evenity in U.S. market

recently, Amgen announced the launch of the new(http://of osteoporo
sis in the US marketEvenity was approved a week ago by the u.SFDA(http://for treatment of osteoporosis in postmenopausal women at high risk of fracturesit is estimated that one in two postmenopausal women in the United States has osteoporosis, which makes them highly susceptible to fracturesBut it also announced the price of the drug, $1,825 per dose, and $21,900 for the entire course of treatment (12 months)Evenity's indications in the United States are: treatment of osteoporosis in postmenopausal women with a high risk of fractures, or in patients who fail or are intolerant of other available osteoporosis therapy treatmentsThe metabolic effect soutcomes of thesynthetic(http://) of Evenity weakens after 12 months of treatment, so the treatment is limited to 12 monthsHowever, since osteoporosis is a chronic disease, once the patient has completed the entire course of treatment, it may also be necessary to consider the continued use of anti-reabsorbent sedativesEvenity has a dual role in increasing bone formation and reducing bone absorption, thereby increasing bone density and reducing the risk of fractures Evenity is the first and only new osteoporosis drug in the U.S market with a dual effect of increased bone formation and reduced bone absorption 　　It should be noted, however, that Evenity's drug (http:// label sits with a black-box warning that using the drug may increase the risk of heart attack, stroke and cardiovascular death